Canaccord Adams Maintains a 'Buy' on Obagi Medical Products (OMPI); Raises PT
OMPI Hot Sheet
Rating Summary:2 Buy, 3 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 16 | Down: 7 | New: 23
Canaccord Adams maintains a 'Buy' on Obagi Medical Products (Nasdaq: OMPI), raises price target from $16 to $17.50.
Canaccord analyst says, "Obagi Medical reported Q3/09 results with revenues of $24.9M and EPS of $0.14. Revenues fell below our estimate for $25.4M and consensus estimates for $25.3M, while EPS in the quarter were in line with expectations. Management offered guidance for the Q4/09, expecting revenues of $25M-$27M and EPS of $0.16-$0.18. Guidance was in line with current expectations...Seasonal weakness impacted product sales in the quarter; however, several sales
initiatives, new account growth, and strength from the international markets suggest that business is moving in the right direction for 2010...We are raising our price target on Obagi Medical to $17.50 from $16.00. Our price target is based on a 23.6x PE multiple applied to our 2010E EPS of $0.75."
To see more analyst ratings on OMPI Click Here.
Canaccord analyst says, "Obagi Medical reported Q3/09 results with revenues of $24.9M and EPS of $0.14. Revenues fell below our estimate for $25.4M and consensus estimates for $25.3M, while EPS in the quarter were in line with expectations. Management offered guidance for the Q4/09, expecting revenues of $25M-$27M and EPS of $0.16-$0.18. Guidance was in line with current expectations...Seasonal weakness impacted product sales in the quarter; however, several sales
initiatives, new account growth, and strength from the international markets suggest that business is moving in the right direction for 2010...We are raising our price target on Obagi Medical to $17.50 from $16.00. Our price target is based on a 23.6x PE multiple applied to our 2010E EPS of $0.75."
To see more analyst ratings on OMPI Click Here.
You May Also Be Interested In
- Barclays Cuts Estimates and Price Target on ADP (ADP); Mixed Data From Investor Day
- Needham & Company Maintains a 'Hold' on Teva Pharma (TEVA); Adjusting Estimates
- Nomura Securities Maintains a 'Neutral' on Tiffany & Co. (TIF); Cutting Estimates and Price Target
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Canaccord AdamsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
